Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Giuseppe Malleo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5467-2628; OpenAlex author ID A5025062457. Sources: ClinicalTrials.gov.

Their work

Papers
102 (first author 11, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
415
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 2 papers · 2017: 4 papers · 2018: 7 papers · 2019: 4 papers · 2020: 15 papers · 2021: 14 papers · 2022: 9 papers · 2023: 10 papers, 1 trial · 2024: 9 papers · 2025: 10 papers · 2026: 16 papers

Papers 50 of 102

  1. The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol. Co-author DOI 10.1002/gin2.70074↗
  2. Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer. Co-author DOI 10.1002/ueg2.70187↗
  3. Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Co-author DOI 10.1007/s00423-026-04291-0↗
  4. Pancreatic cancer surgery in Italy: an updated snapshot from a national multicentre analysis of outcomes by hospital volume. Co-author DOI 10.1007/s13304-026-02813-5↗
  5. Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results f… Co-author DOI 10.1016/j.eclinm.2026.104190↗
  6. Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117033↗
  7. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  8. High fidelity of Claudin-18.2 expression in primary and matched metastatic (lymph nodes, peritoneum, and liver) pancreatic ductal adenocarcinoma: a foundation … Co-author DOI 10.1016/j.humpath.2025.106014↗
  9. CT texture analysis and delta radiomics in predicting R0 resection after preoperative chemotherapy in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2026.102900↗
  10. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the … Co-author DOI 10.1016/s0140-6736(25)01685-x↗
  11. Splenic hilum nodal involvement in resected left-sided pancreatic cancer: meta-analysis. Co-author DOI 10.1093/bjsopen/zrag153↗
  12. Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. Co-author DOI 10.1093/jnci/djag235↗
  13. Morphologic Characterization of Pancreatic Ductal Adenocarcinoma following Post-neoadjuvant Pancreatectomy and Clinical Value of Intratumor Heterogeneity. Co-author DOI 10.1097/sla.0000000000006565↗
  14. KDM6 Histone Demethylases Tune Pancreatic Cancer Plasticity. Co-author DOI 10.1158/0008-5472.can-25-3126↗
  15. Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19218-8↗
  16. ASO Visual Abstract: Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19370-1↗
  17. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  18. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characte… Co-author DOI 10.1002/path.6437↗
  19. Local ablation disrupts immune evasion in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217327↗
  20. MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC. Co-author DOI 10.1038/s41586-025-08721-9↗
  21. Resection to Exploration Ratios and Associated Outcomes in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006197↗
  22. Reappraising the Role of Intraoperative Neck Margin Revision in Postneoadjuvant Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Multi-institution… Co-author DOI 10.1097/sla.0000000000006322↗
  23. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  24. Carbohydrate Antigen 19-9 Delta Function for Survival Prediction in Borderline Pancreatic Cancer. A PANC-PALS Consortium International Multicenter Derivation a… Co-author DOI 10.1097/sla.0000000000006735↗
  25. Expert Judgment Supporting a Bayesian Network to Model the Survival of Pancreatic Cancer Patients. Co-author DOI 10.3390/cancers17020301↗
  26. Surgical and Oncological Outcomes of Minimally Invasive Left Pancreatectomy for Pancreatic Cancer: Robotic vs. Laparoscopic Approach. Co-author DOI 10.3390/curroncol32070376↗
  27. Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. First author DOI 10.1001/jamasurg.2024.2485↗
  28. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. Co-author DOI 10.1016/j.ejca.2023.113430↗
  29. Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery. Co-author DOI 10.1097/sla.0000000000006094↗
  30. Cure Probabilities After Resection of Pancreatic Ductal Adenocarcinoma: A Multi-Institutional Analysis of 2554 Patients. First author DOI 10.1097/sla.0000000000006166↗
  31. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  32. Adjuvant Therapy After Upfront Resection of Resectable Pancreatic Cancer: Patterns of Omission and Use-A Prospective Real-Life Study. First author DOI 10.1245/s10434-024-14951-4↗
  33. ASO Author Reflections: Adjuvant Therapy for Resectable Pancreatic Cancer in the Real World-Not as Common as One Might Think. First author DOI 10.1245/s10434-024-15014-4↗
  34. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  35. The Difficulty of Detecting Occult Metastases in Patients with Potentially Resectable Pancreatic Cancer: Development and External Validation of a Preoperative … Co-author DOI 10.3390/jcm13061679↗
  36. A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic te… Co-author DOI 10.1016/j.esmoop.2023.100881↗
  37. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. Co-author DOI 10.1016/j.modpat.2023.100251↗
  38. A dynamic analysis of empirical survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2022.11.015↗
  39. Pathological staging in postneoadjuvant pancreatectomy for pancreatic cancer: implications for adjuvant therapy. First author DOI 10.1093/bjs/znad146↗
  40. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  41. CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal… First author DOI 10.1245/s10434-022-12622-w↗
  42. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  43. Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective,… Co-author DOI 10.3389/fnut.2023.1065294↗
  44. Independent effect of fat-to-muscle mass ratio at bioimpedance analysis on long-term survival in patients receiving surgery for pancreatic cancer. Co-author DOI 10.3389/fnut.2023.1118616↗
  45. Corrigendum: Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: a r… Co-author DOI 10.3389/fnut.2023.1212436↗
  46. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metas… Co-author DOI 10.1007/s00428-021-03205-3↗
  47. Liver metastases in pancreatic ductal adenocarcinoma: a predictive model based on CT texture analysis. Co-author DOI 10.1007/s11547-022-01548-8↗
  48. Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Co-author DOI 10.1016/j.critrevonc.2021.103571↗
  49. Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004552↗
  50. A Pretreatment Prognostic Score to Stratify Survival in Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000004845↗

Trials 1

  1. FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma Principal investigator NCT05466799↗

Closest collaborators

The 25 strongest of 415 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Roberto Salvia · 73 shared papers, 2011–2026 · strength 10.04
  2. Salvatore Paiella · 40 shared papers, 2018–2026 · strength 5.64
  3. Claudio Bassi · 50 shared papers, 2011–2025 · strength 5.38
  4. Gabriella Lionetto Lionetto · 22 shared papers, 2021–2026 · strength 4.03
  5. Fabio Casciani · 19 shared papers, 2018–2026 · strength 3.60
  6. Claudio Luchini · 23 shared papers, 2016–2026 · strength 3.47
  7. Michèle Milella · 22 shared papers, 1 shared trial, 2020–2026 · strength 3.37
  8. Massimo Falconi · 20 shared papers, 2020–2026 · strength 3.28
  9. Aldo Scarpa Scarpa · 25 shared papers, 2016–2026 · strength 3.24
  10. Laura Maggino · 28 shared papers, 2016–2026 · strength 3.10
  11. Matteo De Pastena · 15 shared papers, 2018–2026 · strength 2.10
  12. Alessandro Esposito · 13 shared papers, 2018–2026 · strength 1.93
  13. Giovanni Marchegiani · 20 shared papers, 2011–2024 · strength 1.91
  14. Stefano Crippa · 10 shared papers, 2022–2026 · strength 1.89
  15. Erica Secchettin · 14 shared papers, 2018–2026 · strength 1.82
  16. Giulio Belfiori · 9 shared papers, 2023–2026 · strength 1.75
  17. Mirko D’Onofrio · 14 shared papers, 2011–2026 · strength 1.68
  18. Antonio Pea · 9 shared papers, 2021–2026 · strength 1.51
  19. Paola Mattiolo · 9 shared papers, 2020–2026 · strength 1.48
  20. Rita Teresa Lawlor · 11 shared papers, 2017–2026 · strength 1.37
  21. Michele Reni · 6 shared papers, 2022–2026 · strength 1.24
  22. Marc G. Besselink · 9 shared papers, 2018–2026 · strength 1.22
  23. Riccardo De Robertis Lombardi · 7 shared papers, 2018–2026 · strength 1.10
  24. Alessandro Zerbi · 9 shared papers, 2016–2026 · strength 1.05
  25. Giovanni Butturini · 11 shared papers, 2011–2025 · strength 1.01

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.